This week, the FDA will decide whether to approve Vertex Pharmaceuticals' non-opioid painkiller. Vertex believes pain could ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on ...

Big Issues Changemakers in health and disability are working to improve the lives of those marginalised by society.

A Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

Some people with cystic fibrosis still do not have access to the life-changing modulator therapy drugs, despite wider EMA ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...